Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
ATZ-Fachkongress

Chassis.tech plus 2024


4 Kongresse in einer Veranstaltung

Treffen Sie in München die Fachleute von Chassis, Lenkung, Bremsen sowie Reifen/Räder.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Industrial Challenges of Recombinant Proteins Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

Insights on the Formulation of Recombinant Proteins

verfasst von : Rita Ribeiro, Teresa Raquel Abreu, Ana Catarina Silva, João Gonçalves, João Nuno Moreira

Erschienen in: Current Applications of Pharmaceutical Biotechnology

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Recombinant proteins are large and complex molecules, whose therapeutic activity highly depends on their structure. Formulation of biopharmaceuticals aims at stabilizing protein conformation, promoting its efficacy, and preventing safety concerns, such as immunogenicity. Currently, the rational design of formulations is possible due to the availability of several techniques for molecule characterization and an array of both well-known and new excipients. Also, high-throughput technologies and Quality by Design approaches are trending and have been contributing to the advancement of the field. Still, there is a search for alternatives that ensure quality of the medicines through its life cycle, particularly for highly concentrated formulations, such as monoclonal antibodies. There is also a demand for strategies that improve protein delivery and more comfortable administration to the patients, especially with the arising of recombinant proteins in the treatment of chronic diseases, such as autoimmune conditions or heart diseases. In this chapter, current and future advancements regarding recombinant protein formulation and its impact in drug development and approval will be addressed.

Graphical Abstract

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Industrial Challenges of Recombinant Proteins
Nächstes Kapitel Therapeutic Antibody Engineering and Selection Strategies
Literatur
1.
Dill KA, Maccallum JL (2012) The protein-folding problem, 50 years on. Science 338:1042–1047PubMedCrossRef
2.
3.
Goswami S, Wang W, Arakawa T, Ohtake S (2013) Developments and challenges for mAb-based therapeutics. Antibodies 89:452–500CrossRef
4.
Krause ME, Sahin E (2019) Chemical and physical instabilities in manufacturing and storage of therapeutic proteins. Curr Opin Biotechnol 60:159–167PubMedCrossRef
5.
Randolph TW, Carpenter JF (2007) Engineering challenges of protein formulations. Am Inst Chem Eng J 53:1902–1907CrossRef
6.
Pisal DS, Kosloski MP, Balu-iyer SV (2009) Delivery of therapeutic proteins. J Pharm Sci 99:2557–2575CrossRef
7.
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27:544–575PubMedCrossRef
8.
Soulby AJ, Heal JW, Barrow MP, Roemer RA, Connor PBO (2015) Does deamidation cause protein unfolding? A top-down tandem mass spectrometry study. Protein Sci 24:850–860PubMedPubMedCentralCrossRef
9.
Tyler-cross R, Schirchs V (1991) Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 266:22549–22556PubMed
10.
Diepold K et al (2012) Simultaneous assessment of asp isomerization and asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One 7:1–11CrossRef
11.
Gervais D (2016) Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. J Chem Technol Biotechnol 91:569–575CrossRef
12.
Parkins DA, Lashmar UT (2000) The formulation of biopharmaceutical products. Pharm Sci Technol Today 3:129–137PubMedCrossRef
13.
Stadtman ER (1990) Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9:315–325PubMedCrossRef
14.
Ha E, Wang WEI, Wang YJ (2002) Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91:2252–2264PubMedCrossRef
15.
Torosantucci R, Schöneich C, Jiskoot W (2014) Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res 31:541–553PubMedCrossRef
16.
Li S, Schoneich C, Borchardt RT (1995) Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48:490–500PubMedCrossRef
17.
Wang WEI et al (2006) Antibody structure, instability, and formulation. J Pharm Sci 96:1–26CrossRef
18.
Kiese S, Papppenberger A, Friess W, Mahler H (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347–4366PubMedCrossRef
19.
Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129–188PubMedCrossRef
20.
Carpenter BJF, Kendrick BS, Chang BS, Manning MC, Randolph TW (1999) Inhibition of stressed-induced aggregation of protein therapeutics. Methods Enzymol 309:236–255PubMedCrossRef
21.
Kueltzo LA, Wang WEI, Randolph TW, Carpenter JF (2008) Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze–thawing. J Pharm Sci 97:1801–1812PubMedCrossRef
22.
Dias CL et al (2010) The hydrophobic effect and its role in cold denaturation. Cryobiology 60:91–99PubMedCrossRef
23.
Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325–1336PubMedCrossRef
24.
Joubert MK et al (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287:25266–25279PubMedPubMedCentralCrossRef
25.
Andersen CB, Manno M, Rischel C, Thórólfsson M, Martorana V (2010) Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci 19:279–290PubMedCrossRef
26.
Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4:298–306PubMedCrossRef
27.
Chiti F, Stefani M, Ramponi G, Dobson CM (2003) Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424:805–808PubMedCrossRef
28.
Nielsen L, Frokjaer S, Brange J, Uversky VN, Fink AL (2001) Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 40:8397–8409PubMedCrossRef
29.
Agrawal NJ et al (2011) Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm 100:5081–5095
30.
31.
Pandya A, Howard MJ, Zloh M, Dalby PA (2018) An evaluation of the potential of NMR spectroscopy and computational modelling methods to inform biopharmaceutical formulations. Pharmaceutics 10:1–24CrossRef
32.
ICH (1999) ICH Q6B – specifications: test procedures and acceptance criteria for biotechnological/biological products. 1–16
33.
Beck A, Wagner-rousset E, Ayoub D, van Dorsselaer A, Sanglier-cianférani S (2013) Characterization of therapeutic antibodies and related products. Anal Chem 85:715–736PubMedCrossRef
34.
Crommelin D (2013) Formulation of biotech products, including biopharmaceutical considerations. In: Pharmaceutical biotechnology. CRC Press, Boca Raton, pp 69–96CrossRef
35.
Angkawinitwong U, Sharma G, Khaw PT, Brocchini S (2015) Solid-state protein formulations. Ther Deliv 6:59–82PubMedCrossRef
36.
Solá RJ, Griebenow KAI (2010) Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98:1223–1245CrossRef
37.
Jorgensen L, Hostrup S, Moeller EH, Grohganz H (2009) Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients. Expert Opin Drug Deliv 6:1219–1230PubMedCrossRef
38.
Peters B et al (2016) Effects of cooling rate in microscale and pilot scale freeze-drying – variations in excipient polymorphs and protein secondary structure. Eur J Pharm Sci 95:72–81PubMedCrossRef
39.
Gervasi V et al (2018) Parenteral protein formulations: an overview of approved products within the European Union. Eur J Pharm Biopharm 131:8–24PubMedCrossRef
40.
Garidel P, Kuhn AB, Schäfer LV, Karow-zwick AR, Blech M (2017) High-concentration protein formulations: how high is high. Eur J Pharm Biopharm 119:353–360PubMedCrossRef
41.
Hawe A, Frieß W (2007) Formulation development for hydrophobic therapeutic proteins. Pharm Dev Technol 12:223–237PubMedCrossRef
42.
Tedeschi G, Mangiagalli M, Chmielewska S, Natalello A, Brocca S (2017) Aggregation properties of a disordered protein are tunable by pH and depend on its net charge per residue. Biochim Biophys Acta 1861:2543–2550CrossRef
43.
44.
Roethlisberger D, Mahler H, Altenburger U, Pappenberger A (2016) If euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms? J Pharm Sci 106:1–11
45.
Bahrenburg S, Karow AR, Garidel P (2015) Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications. Biotechnol J 10:610–622PubMedCrossRef
46.
Shire SJ (2009) Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708–714PubMedCrossRef
47.
Arakawa T, Tsumoto K, Kita Y, Chang B, Ejima D (2007) Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 33:587–605PubMedCrossRef
48.
Shukla D, Trout BL (2011) Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility. J Phys Chem 115:11831–11839CrossRef
49.
Al-hussein A, Gieseler H (2013) Investigation of histidine stabilizing effects on LDH during freeze-drying. J Pharm Sci 102:813–826PubMedCrossRef
50.
Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1–60PubMedCrossRef
51.
Pikal MJ, Dellerman KM, Roy ML, Riggin RM (1991) The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm Res 8:427–436PubMedCrossRef
52.
Akers MJ (2002) Excipient-drug interactions in parenteral formulations. J Pharm Sci 91:2283–2300PubMedCrossRef
53.
Khan TA, Mahler H, Kishore RSK (2015) Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm 97:60–67PubMedCrossRef
54.
Goyal MK, Roy I, Amin A, Banerjee UC, Bansal AK (2010) Stabilization of lysozyme by benzyl alcohol: surface tension and thermodynamic parameters. J Pharm Sci 99:4149–4161PubMedCrossRef
55.
Hutchings RL, Singh SM, Cabello-Villegas J, Mallela KMG (2013) Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci 102:365–376PubMedCrossRef
56.
Bis RL, Singh SM, Cabello-villegas J, Mallela KMG (2014) Role of benzyl alcohol in the unfolding and aggregation of interferon alpha-2a. J Pharm Sci 26:1–9
57.
Heljo P, Ross A, Zarraga IE, Pappenberger A, Mahler H-C (2015) Interactions between peptide and preservatives: effects on peptide self-interactions and antimicrobial efficiency in aqueous multi-dose formulations. Pharm Res 32:3201–3212PubMedCrossRef
58.
Jezek J et al (2013) Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv 10:811–828PubMedCrossRef
59.
Kocha T, Yamaguchi M, Ohtaki H, Fukuda T, Aoyagi T (1996) Hydrogen peroxide-mediated degradation of protein: different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin. Biochim Biophys Acta 1337:319–326CrossRef
60.
Morefield GL et al (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588–1595PubMedCrossRef
61.
Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22:411–416PubMedCrossRef
62.
Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505–517PubMedCrossRef
63.
Buonsanti C, Oro UD (2017) Discovery of immune potentiators as vaccine adjuvants. In: Immunopotentiators in modern vaccines. Elsevier, Amsterdam, pp 85–104CrossRef
64.
EMEA/CPMP (2004) Guideline on adjuvants in vaccines. 1–18
65.
Jones LS et al (2005) Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 280:13406–13414PubMedCrossRef
66.
Fox CB, Kramer RM, Lucien Barnes V, Dowling QM, Vedvick TS (2013) Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines Rev 1:7–20CrossRef
67.
Kaurav M et al (2018) Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage. Artif Cells Nanomed Biotechnol 46:S818–S831PubMedCrossRef
68.
Yanan C, Ping C, Binlong C, Suxin L, Hua G (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 43:519–530CrossRef
69.
70.
71.
EMEA/CHMP (2015) Guideline on similar biological medicinal products. pp 1–7
72.
73.
FDA (2015) Scientific considerations in demonstrating biosimilarity to a reference product. pp 1–24
74.
EMEA/CHMP (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. pp 1–13
75.
Kesik-brodacka M (2018) Progress in biopharmaceutical development. Int Union Biochem Mol Biol 65:306–322
76.
Anour R (2014) Biosimilars versus ‘biobetters’ – a regulator’s perspective. Generics Ans Biosimilars Initiat J 3:166–167CrossRef
77.
Ismael G et al (2012) Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869–878PubMedCrossRef
78.
Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24:504–514PubMedCrossRef
79.
Shnek DR, Hostettler DL, Bell MA, Olinger JM, Frank BH (1998) Physical stress testing of insulin suspensions and solutions. J Pharm Sci 87:1459–1465PubMedCrossRef
80.
Franks F (1998) Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm 45:221–229PubMedCrossRef
81.
Patel SM et al (2017) Lyophilized drug product cake appearance: what is acceptable? J Pharm Sci 106:1706–1721PubMedCrossRef
82.
Mensink MA, Frijlink HW, van der Voort K, Hinrichs WLJ (2017) How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions. Eur J Pharm Biopharm 114:288–295PubMedCrossRef
83.
Cao W et al (2013) Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies. Eur J Pharm Biopharm 85:287–293PubMedCrossRef
84.
FDA (1999) Container closure systems for packaging human drugs and biologics. pp 1–41
85.
Wang M et al (2018) Interactions between biological products and product packaging and potential approaches to overcome them. AAPS PharmSciTech 19:3681–3686PubMedCrossRef
86.
Raghani A, Li K, Bussiere JL, Bercu JP, Qiu J (2018) Process-related impurities in biopharmaceuticals. In: ICH quality guidelines: an implementation guide. Wiley, Hoboken, pp 487–507
87.
Dipaolo B, Pennetti A, Nugent L, Venkat K, Venkat K (1999) Monitoring impurities in biopharmaceuticals produced by recombinant technology. Pharm Sci Technol Today 2:70–82PubMedCrossRef
88.
Florence AT, Attwood D (2016) Adverse events: the role of formulations and delivery systems. In: Physicochemical principles of pharmacy. Macmillan, Basingstoke, pp 481–511
89.
Elder DP, Kuentz M, Holm R (2015) Pharmaceutical excipients – quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci 87:1–12
90.
WHO (2013) Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. pp 1–91
91.
Nally J (2007) Good manufacturing practices for pharmaceuticals. CRC Press, Boca Raton
92.
EMEA/CHMP (2007) Guideline on excipients in the dossier for application for marketing authorization of a medical product. pp 1–12
93.
94.
Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740PubMedCrossRef
95.
96.
Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:4–9CrossRef
97.
Li J et al (2019) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Am Soc Hematol 98:3241–3249
98.
Schernthaner G (1993) Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155–165PubMedCrossRef
99.
Dumont J, Euwart D, Mei B, Estes S, Kshirsagar R (2016) Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol 36:1110–1122PubMedCrossRef
100.
Robinson AS (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol Bioeng 7:1473–1484
101.
Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897–903PubMedCrossRef
102.
Kijanka G et al (2018) Submicron size particles of a murine monoclonal antibody are more immunogenic than soluble oligomers or micron size particles upon subcutaneous administration in mice. J Pharm Sci 107:2847–2859PubMedCrossRef
103.
Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:501–507CrossRef
104.
The United States Pharmacopeial Convention (2012) <788> Particulate matter in injections. pp 1–3
105.
European Pharmacopoeia (2007) 2.9.19. Particulate contamination: sub-visible particles. pp 300–302
106.
European Pharmacopoeia (2007) 2.9.20. Particulate contamination: visible particles. p 302
107.
Ito H, Nakashima T, So T, Hirata M, Inoue M (2003) Immunodominance of conformation-dependent B-cell epitopes of protein antigens. Biochem Biophys Res Commun 308:770–776PubMedCrossRef
108.
Casadevall N, Nataf J, Viron B, Kolta A, Patrick M (2002) Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475PubMedCrossRef
109.
Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555–561PubMedCrossRef
110.
Groot, A. S. De, Mcmurry, J. & Moise, L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8, 1–7 (2008)
111.
Shankar G et al (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides – harmonized terminology and tactical recommendations. AAPS J 16:658–673PubMedPubMedCentralCrossRef
112.
EMEA/CHMP (2007) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. pp 1–18
113.
EMEA/CHMP (2012) Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. pp 1–10
114.
FDA (2016) Assay development and validation for immunogenicity testing of therapeutic protein products. pp 1–31
115.
Shah M (2018) New perspectives on protein aggregation during biopharmaceutical development. Int J Pharm 552:1–6PubMedCrossRef
116.
Bookbinder LH et al (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230–241PubMedCrossRef
117.
Schiefelbein L et al (2010) Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation. Eur J Pharm Biopharm 76:342–350PubMedCrossRef
118.
Du W, Klibanov AM (2011) Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol Bioeng 108:632–636PubMedCrossRef
119.
Serno T, Geidobler R, Winter G (2011) Protein stabilization by cyclodextrins in the liquid and dried state. Adv Drug Deliv Rev 63:1086–1106PubMedCrossRef
120.
121.
Kozarewicz P, Loftsson T (2018) Novel excipients – regulatory challenges and perspectives – the EU insight. Int J Pharm 546:176–179PubMedCrossRef
122.
FDA (2005) Nonclinical studies for the safety evaluation of pharmaceutical excipients. pp 1–9
123.
Zhu L, Xu H (2015) The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Dove Press J 9:923–942
124.
Fayad F et al (2018) Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study. Dove Press J 12:1619–1625
125.
Mahato RI, Narang AS, Th L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153–214PubMedCrossRef
126.
Barnett AH, Bellary S (2007) Inhaled human insulin (Exubera®): clinical profile and patient considerations. Vasc Health Risk Manag 3:83–91
127.
Hanson LR, Ii WHF (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:1–4CrossRef
128.
Chaulagain B, Jain A, Tiwari A, Verma A, Jain SK (2018) Passive delivery of protein drugs through transdermal route. Artif Cells Nanomed Biotechnol 46:S472–S487CrossRef
129.
130.
Kayser O, Warzecha H (2012) Pharmaceutical biotechnology drug discovery and clinical applications. Wiley-Blackwell, HobokenCrossRef
131.
Philippart M et al (2016) Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug Res 66:113–120
132.
Vaishya R, Khurana V, Patel S, Mitra AK (2015) Long-term delivery of protein therapeutics. Expert Opin Drug Deliv 12:415–440PubMedCrossRef
133.
Crommelin DJA, Hawe A, Jiskoot W (2019) Formulation of biologics including biopharmaceutical considerations. In: Pharmaceutical biotechnology. Springer, Berlin, pp 83–103CrossRef
134.
Ye C, Venkatraman S (2019) The long-term delivery of proteins and peptides using micro/nanoparticles: overview and perspectives. Ther Deliv 10:10–13CrossRef
135.
Vermonden T, Censi R, Hennink WE (2012) Hydrogels for protein delivery. Chem Rev 112:2853–2888PubMedCrossRef
136.
Capelle MAH, Arvinte T (2008) High-throughput formulation screening of therapeutic proteins. Drug Discov Today Technol 5:71–79CrossRef
137.
Senisterra GA, Finerty PJ (2009) High throughput methods of assessing protein stability and aggregation. Mol Biosyst 5:217–223PubMedCrossRef
138.
Carbonell F, Iturria-Medina Y, Evans AC (2018) Mathematical modeling of protein misfolding mechanisms in neurological diseases: a historical overview. Front Neurol 9:1–16CrossRef
139.
Andrews JM, Roberts CJ (2007) A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1.aggregation with pre-equilibrated unfolding. J Phys Chem 111:7897–7913CrossRef
140.
Mulder NJ, Kersey P, Pruess M, Apweiler R (2008) In silico characterization of proteins: UniProt, InterPro and Integr8. Mol Biotechnol 38:165–177PubMedCrossRef
141.
Kirchmair J et al (2008) The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J Med Chem 51:7021–7039PubMedCrossRef
142.
Tamizi E, Jouyban A (2016) Forced degradation studies of biopharmaceuticals: Selection of stress conditions. Eur J Pharm Biopharm 98:26–46PubMedCrossRef
143.
144.
145.
Capelle MAH, Gurny R, Arvinte T (2007) High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm 65:131–148PubMedCrossRef
146.
Ducret A, Oostveen IVAN, Eng JK, In JRY, Aebersold R (1998) High throughput protein characterization by automated reverse-phase chromatography/electrospray tandem mass spectrometry. Protein Sci 7:706–719PubMedPubMedCentralCrossRef
147.
Zhao HUI et al (2010) Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 99:2279–2294PubMedCrossRef
148.
Wang W, Ohtake S (2019) Science and art of protein formulation development. Int J Pharm 568:118505PubMedCrossRef
149.
Perez-ramírez B, Guziewicz N, Simler R, Sreedhara A (2015) Approaches for early developability assessment of proteins to guide quality by design of liquid formulations. In: Quality by design for biopharmaceutical drug product development. Springer, Berlin, pp 87–114CrossRef
150.
Jarasch A et al (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104:1885–1898PubMedCrossRef
151.
Zurdo J (2013) Developability assessment as an early de-risking tool for biopharmaceutical development. Pharm Bioprocess 1:29–50CrossRef
152.
ICH (2009) ICH Q8(R2) – pharmaceutical development. pp 1–24
153.
Grant Y, Matejtschuk P, Bird C, Wadhwa M, Dalby PA (2012) Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor. Biotechnol Lett 34:641–648PubMedCrossRef
154.
ICH (2005) ICH Q9 – quality risk management. pp 1–19
155.
Moreton C (2009) Functionality and performance of excipients in a quality-by-design world. Am Pharm Rev:32–35
Metadaten
Titel
Insights on the Formulation of Recombinant Proteins
verfasst von
Rita Ribeiro
Teresa Raquel Abreu
Ana Catarina Silva
João Gonçalves
João Nuno Moreira
Copyright-Jahr
2020
Verlag
Springer International Publishing
Buch
Current Applications of Pharmaceutical Biotechnology

Print ISBN: 978-3-030-40463-5

Electronic ISBN: 978-3-030-40464-2

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/10_2019_119

Premium Partner

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen. 

    Zur Marktübersicht
    Bildnachweise